Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth

BACKGROUND: Increased exposure to multitargeted kinase inhibitor sunitinib is associated with improved outcome, emphasizing the importance of maintaining adequate dosing and drug levels. The currently approved schedule (50 mg daily, four weeks on, two weeks off) precludes further dose-intensificatio...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Exp Clin Cancer Res
Hlavní autoři: Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Poel, Dennis, Peters, Godefridus J., Griffioen, Arjan W., Verheul, Henk M. W.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2016
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5013589/
https://ncbi.nlm.nih.gov/pubmed/27604186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-016-0411-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky